Relapsed or refractory acute myeloid leukemia (R/R AML) remains a therapeutic challenge, with standard high‑dose cytarabine-based salvage regimens achieving complete remission (CR) rates of around 50%. In the phase 1/2 RELAX trial, adding venetoclax (VEN) to high‑dose cytarabine and mitoxantrone (HAM) was considered sa...
A. Berdel, C. Röllig, C. Burkhard-Meier et al.· Haematologica· 0 citations
INTRODUCTION
Long-term outcomes of allogeneic hematopoietic cell transplantation (HCT) are improving, increasing the relevance of secondary malignancies, including lung cancer. The clinical utility of immune checkpoint inhibitors (ICIs) in this setting remains unclear and concerns regarding graft-versus-host disease (G...
M. Rost, C. Wehr, Miriam Mozaffari Jovein et al.· Lung Cancer· 0 citations
A deeper understanding of the brain metastatic ecosystem may enable the development of more effective, biology-driven therapeutic approaches for NSCLC BM.
Marcel Kemper, Lea Reitnauer, A. Leonetti et al.· Cancer Biome and Targeted Th...· 0 citations
A reliable method to quantify several tyrosine kinase inhibitors from plasma and capillary blood, which is intended for TDM purposes in clinical practice is developed.
